In this Tools of the Trade article, Chiara Cattaneo describes the development of HANSolo, a high-throughput genetic platform for the personalized identification of CD4+ and CD8+ T cell-recognized (neo)antigens, that can be used to generate patient-specific TCR gene therapies or cancer vaccines.